TuHURA Biosciences Files 8-K

Ticker: HURA · Form: 8-K · Filed: Jun 12, 2025 · CIK: 1498382

Sentiment: neutral

Topics: financial-statements, exhibits, sec-filing

TL;DR

TuHURA filed an 8-K with financial statements and exhibits as of June 6, 2025.

AI Summary

TuHURA Biosciences, Inc. filed an 8-K on June 12, 2025, reporting events as of June 6, 2025. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text.

Why It Matters

This filing indicates TuHURA Biosciences is providing updated financial statements and exhibits to the SEC, which is standard procedure but important for investors to review for company financial health.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, not indicating any immediate negative or positive material events.

Key Numbers

Key Players & Entities

FAQ

What specific financial statements or exhibits are being filed?

The filing indicates 'Financial Statements and Exhibits' are being reported, but the specific details are not provided in this summary.

What is the exact date of the earliest event reported?

The earliest event reported is June 6, 2025.

When was this 8-K form filed with the SEC?

The form was filed on June 12, 2025.

What is TuHURA Biosciences, Inc.'s principal executive office address?

The principal executive office is located at 10500 University Dr., Suite 110, Tampa, Florida 33612.

Has TuHURA Biosciences, Inc. operated under any previous names?

Yes, the company was formerly known as Kintara Therapeutics, Inc., DelMar Pharmaceuticals, Inc., and Berry Only Inc.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 12, 2025 regarding TuHURA Biosciences, Inc./NV (HURA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing